camsirubicin

Camsirubicin is a novel analog of doxorubicin, designed to retain the anti-cancer activity of doxorubicin while reducing its risk of irreversible heart damage. Like doxorubicin, it is an anthracycline chemotherapy agent that works primarily by intercalating into DNA and inhibiting DNA topoisomerase 2-alpha, leading to DNA strand breaks and apoptosis in cancer cells. Camsirubicin is being developed as a potential first-line treatment for advanced soft tissue sarcoma, aiming to replace doxorubicin due to its improved cardiac safety profile. In clinical studies, camsirubicin has shown encouraging efficacy and safety data in patients with advanced soft tissue sarcoma, with no drug-related clinical cardiac toxicities observed[6][8].

Other names

5-imino-13-deoxydoxorubicin